A fused [3.3.0]-neoglycoside lactone derived from glucuronic acid
Matthew W Schombs1, Ryan A Davis, James C Fettinger
1Department of Chemistry, University of California, One Shields Avenue, Davis, CA 95616, USA.
Abstract:
The bridged next-generation aminoglycoside (neoglycoside), 1-deoxy-1-[(methoxy)methylamino)]-2,5-di-O-triethylsilyl-β-D-glucofuranurono-γ-lactone {systematic name: (3S,3aS,5R,6R,6aS)-5-[methoxy(methyl)amino]-3,6-bis[(triethylsilyl)oxy]-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-2-one}, C20H41NO6Si2, was synthesized in a one-pot manner from commercially available D-glucuronic acid. This structure supports the properties associated with the anomeric effect for furanosides and can be employed to provide insight into the mechanisms by which alkoxyamine-appended natural products derive their enhanced biological activity. To the best of our knowledge, this is the first published crystal structure of a bicyclic neoglycoside and is the first neoglycoside to be completely and unambiguously characterized.
Related Concept Videos
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Phase II Reactions: Glucuronidation
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Proteoglycans
Drug Metabolism: Phase II Reactions
Peptidoglycan Synthesis

